Related Experiment Videos

Cytokines enhance opsonophagocytosis of type III group B Streptococcus

J R Campbell1, M S Edwards

  • 1Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Abstract

Insights

Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances neonatal neutrophil killing of Group B Streptococcus (GBS). This suggests GM-CSF, potentially with immunoglobulin therapy, could improve infant defense against GBS infections.

Area of Science:

  • Immunology
  • Neonatal Medicine
  • Infectious Disease

Background:

  • Neutrophil (polymorphonuclear leukocyte, PMN) mediated killing is crucial for host defense against Group B Streptococcus (GBS).
  • Neonates often exhibit impaired PMN function, contributing to susceptibility to GBS infection.

Purpose of the Study:

  • To investigate if cytokines like TNF-alpha, G-CSF, or GM-CSF can enhance neonatal PMN-mediated killing of type III GBS.
  • To assess the role of FcRIII receptors in GM-CSF-augmented PMN killing of GBS.

Main Methods:

  • Adult and neonatal PMNs were incubated with TNF-alpha, G-CSF, or GM-CSF.
  • PMN-mediated killing of type III GBS was evaluated using an in vitro opsonophagocytic assay.
  • FcRIII receptor involvement was tested using monoclonal antibody blockade.

Main Results:

  • Cytokine treatment (TNF-alpha, G-CSF, GM-CSF) enhanced GBS killing by both adult and neonatal PMNs.
  • GM-CSF significantly improved killing by neonatal PMNs.
  • GM-CSF's effect was partially mediated by FcRIII receptors and enhanced by specific antibodies.

Conclusions:

  • Granulocyte-colony stimulating factor (G-CSF) enhances neonatal PMN-mediated killing of GBS in vitro.
  • GM-CSF augments PMN killing of GBS, potentially via FcRIII receptors.
  • GM-CSF, possibly combined with intravenous immunoglobulin, may improve neonatal host defense against GBS.

Related Concept Videos